{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.667","upperLimit":"5.83","value":"1.67"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received oral doses of glasdegib tablets 100 mg QD in 28-day cycles on a continuous basis, starting on Day 1 of Cycle 1. LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28 day cycles.","id":"OG000","title":"Phase 2 Unfit: Glasdegib 100 mg + LDAC"}],"paramType":"MEDIAN","populationDescription":"Dose compliant, non CYP3A4 group: dose compliant group participants who did not have administration of any strong or moderate CYP3A4 inhibitors.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 1, 2, 4, and 6 hour post-dose on Cycle 1/Day 10","title":"Tmax of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10","type":"SECONDARY","unitOfMeasure":"Hours"}